Urticarial vasculitis syndrome effectively treated with dapsone and pentoxifylline

Acta Derm Venereol. 1995 Jan;75(1):54-6. doi: 10.2340/00015555755456.

Abstract

Urticarial vasculitis is difficult to treat. We report here on a 40-year-old woman with a 16-year history of idiopathic hypocomplementemic urticarial vasculitis syndrome. Her disease had been resistant to treatment with H1- and H2-blockers, indomethacin, dapsone and interferon alpha but responded to > 25 mg/day prednisolone. Monotherapy with pentoxifylline was also of only minor benefit. Using a combination of dapsone (100 mg/day) and pentoxifylline (1,200 mg/day), we observed a gradual improvement resulting in a complete remission within 8 weeks. Complete control of symptoms could be maintained for 18 months without any serious side-effects. This type of treatment may be of benefit in other therapy-resistant cases of hypocomplementemic urticarial vasculitis syndrome, particularly in view of its excellent tolerance.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antigen-Antibody Complex / analysis
  • Complement C3 / analysis
  • Dapsone / administration & dosage
  • Dapsone / therapeutic use*
  • Drug Combinations
  • Drug Resistance
  • Female
  • Humans
  • Pentoxifylline / administration & dosage
  • Pentoxifylline / therapeutic use*
  • Remission Induction
  • Syndrome
  • Urticaria / drug therapy*
  • Vasculitis, Leukocytoclastic, Cutaneous / drug therapy*

Substances

  • Antigen-Antibody Complex
  • Complement C3
  • Drug Combinations
  • Dapsone
  • Pentoxifylline